BDX Q2 Earnings Top Estimates, Reports $480M COVID-19 Diagnostic Sales; Reaffirms FY21 Guidance

[unable to retrieve full-text content]

View more earnings on BDXSee more from BenzingaClick here for options trades from BenzingaBiden Administration Backs Waiving IP Protections For COVID-19 Vaccines, Pharma Industry Rebukes MoveStealth Bio Stock Almost Doubles After Positive Elamipretide Data In Eye Disease Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


More from: | Category: Medical Device Company News